BioCentury
ARTICLE | Finance

Ebb & Flow

August 31, 2009 7:00 AM UTC

Retail investors got carried away last week on a rumor that Human Genome Sciences Inc. (NASDAQ:HGSI) would be acquired by partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for $30 a share.

On Tuesday, the stock hit a 52-week high of $22.78 mid-day, up $6.33 (38%) from Friday's close. But in the absence of news, the shares fell back to close Friday at $19.80, still a $3.35 (20%) gain on the week...